Didier Sánchez-Ospina, Sebastián Mas-Fontao, Carolina Gracia-Iguacel, Alejandro Avello, Marina González de Rivera, Maddalen Mujika-Marticorena, Emilio Gonzalez-Parra
Uremic toxins (UTs), particularly protein-bound uremic toxins (PBUTs), accumulate in chronic kidney disease (CKD) patients, causing significant health complications like uremic syndrome, cardiovascular disease, and immune dysfunction. The binding of PBUTs to plasma proteins such as albumin presents a formidable challenge for clearance, as conventional dialysis is often insufficient. With advancements in the classification and understanding of UTs, spearheaded by the European Uremic Toxins (EUTox) working group, over 120 molecules have been identified, prompting the development of alternative therapeutic strategies...
March 1, 2024: Journal of Clinical Medicine